NUPLAZID

Peak

pimavanserin tartrate

Acadia Pharmaceuticals

NDAORALTABLETPriority Review

Approved

Apr 2016

Lifecycle

Peak

Competitive Pressure

0/100

Mechanism of Action

unclear. However, the effect of pimavanserin could be mediated through a combination of inverse agonist and antagonist activity at serotonin 5-HT 2A receptors and to a lesser extent at serotonin 5-HT 2C receptors.

Indications (2)

hallucinations delusions associated with Parkinson's disease psychosis

Loss of Exclusivity

LOE Date

Mar 23, 2037

134 months away

Patent Expiry

Mar 23, 2037

Patent Records (5)

Patent #	Expiry	Type	Use Code
7659285	Aug 24, 2026		U-1844
7732615	Jun 3, 2028	SubstanceProduct	—
7601740	Apr 29, 2030	SubstanceProduct	—
10517860	Mar 23, 2037		U-1974
10953000	Mar 23, 2037		U-1974

Company

Acadia Pharmaceuticals

SAN DIEGO, CA

External Resources

DailyMed

Full prescribing information

FDA Drugs@FDA

FDA approval history

RxNorm

Drug nomenclature & identifiers